Table 1.
Ref.
|
Study
|
Intervention
|
Route of FMT administration
|
n
|
Mean MELD score
|
Follow-up
|
|
Bajaj et al[29], 2019 | Phase I | Treatment arm | FMT + SOC | Enema | 10 | 12.5 | 5 mo |
Control arm | SOC | 10 | 12.5 | 5 mo | |||
Bajaj et al[28], 2017 | Phase I | Treatment arm | FMT | Enema | 10 | 13.2 | 5 mo |
Control arm | SOC | 10 | 12 | 5 mo | |||
Woodhouse et al[33], 2019 | Phase III | Treatment arm | FMT + Lactulose | NJ tube | 13 | 12.88 | 3 mo |
Control arm | SOC | 5 | 12.88 | 3 mo | |||
Bloom et al[81], 2019 | Phase II | Treatment arm | FMT | Oral | 7 | 13.9 | 1 mo |
Control arm | SOC | 3 | NA | 1 mo | |||
Mehta et al[30], 2018 | Case series | FMT | Colonoscopy | 10 | 18 | 20 d | |
Kao et al[32], 2016 | Case report | FMT | Colonoscopy | 1 | 10 | 7 d |
FMT: Fecal microbiota transplant; SOC: Standard of care; MELD: Model for end-stage liver disease.